Cargando…
Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I' mode
TRAIL is a promising anticancer agent, capable of inducing apoptosis in a wide range of treatment-resistant tumor cells. In ‘type II' cells, the death signal triggered by TRAIL requires amplification via the mitochondrial apoptosis pathway. Consequently, deregulation of the intrinsic apoptosis-...
Autores principales: | Gillissen, B, Richter, A, Overkamp, T, Essmann, F, Hemmati, P G, Preissner, R, Belka, C, Daniel, P T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674381/ https://www.ncbi.nlm.nih.gov/pubmed/23703388 http://dx.doi.org/10.1038/cddis.2013.67 |
Ejemplares similares
-
Endogenous Bak inhibitors Mcl-1 and Bcl-x(L): differential impact on TRAIL resistance in Bax-deficient carcinoma
por: Gillissen, Bernhard, et al.
Publicado: (2010) -
Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis
por: Gillissen, Bernhard, et al.
Publicado: (2007) -
Contribution of BH3-domain and Transmembrane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax
por: Stehle, Daniel, et al.
Publicado: (2018) -
The great migration of Bax and Bak
por: Edlich, Frank
Publicado: (2015) -
Mitophagy restricts BAX/BAK-independent, Parkin-mediated apoptosis
por: Quarato, Giovanni, et al.
Publicado: (2023)